S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IVVD · Invivyd, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$0.64
-0.00
(-0.53%)
● At close: October 21 at 4:00:00 PM EDT
$0.67
+0.03
(+5.02%)
Overnight:
8:36:52 PM EDT
DAY'S RANGE
$0.64
$0.64
$0.69
52-WEEK RANGE
$0.64
$0.53
$3.07
What's happening
- IVVD is down 0.53% today, trading at $0.64. — Live quote
- Volume today (201,357) is well below its 3-month average of 5,185,470. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.14 actual vs. $-0.11 estimated (-28.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IVVD
-74.23%
vs S&P 500
-87.00%
1-YEAR RETURN
IVVD
-67.69%
vs S&P 500
-82.25%
6-MONTH RETURN
IVVD
-62.77%
3-MONTH RETURN
IVVD
-6.62%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.14
Est. $-0.11
MISS -28.7%
2026-04-26 (Q1 2026)
$-0.13
Est. $-0.07
MISS -73.8%
2026-01-26 (Q4 2025)
$-0.04
Est. $-0.09
BEAT +55.2%
2025-10-26 (Q3 2025)
$-0.06
Est. $-0.08
BEAT +26.5%
Valuation Measures & Ratios
Enterprise Value4$28.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.23
Price / Book71.42
EV4 / Revenue0.49
EV4 / EBITDA—
Profit Margin-183.90%
Operating Margin-192.81%
Return on Equity (ROE8)-59.73%
Return on Assets (ROA9)-48.97%
Avg Volume (3M)5,185,470
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $278.9M | $412.4M | $192.0M | $88.7M | $71.6M |
| P/E | -2.51 | -4.98 | -1.88 | -0.64 | -0.43 |
| Price/Sales | 5.27 | 8.25 | 4.22 | 2.56 | 3.13 |
| Price/Book | 1.54 | 2.03 | 2.06 | 2.07 | 1.32 |
| EV/Revenue | 2.24 | 4.57 | 2.35 | 1.55 | 1.03 |
| ROE | -61.26% | -40.79% | -109.77% | -324.70% | -309.83% |
| ROA | -50.68% | -34.26% | -73.41% | -155.87% | -161.72% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short33,858,191
Change from Prior Settlement+10.81%
% of Float—
Days to Cover (Short Ratio)3.58
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 21.2% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -183.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -67.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IVVD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $13.7M | $13.1M | $11.8M | $11.3M | $9.3M | $2.3M | $0 |
| Operating income | -$45.8M | -$43.1M | -$11.0M | -$15.1M | -$16.9M | -$62.3M | -$49.2M | -$46.1M |
| Net income | -$44.4M | -$41.4M | -$10.5M | -$14.7M | -$16.3M | -$60.7M | -$47.2M | -$43.5M |
| EPS (diluted) | $-0.14 | $-0.13 | $-0.06 | $-0.12 | $-0.14 | $-0.51 | $-0.40 | $-0.38 |
| EPS (basic) | $-0.14 | $-0.13 | $-0.06 | $-0.12 | $-0.14 | $-0.51 | $-0.40 | $-0.38 |
| Operating margin | -$321 | -$314 | -$84 | -$128 | -$150 | -$670 | -$2.2K | — |
| Net margin | -$311 | -$301 | -$80 | -$124 | -$144 | -$653 | -$2.1K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $218.9M | $241.7M | $276.9M | $139.2M | $89.1M | $103.7M | $129.5M | $161.9M |
| Total liabilities | $37.8M | $38.7M | $35.3M | $46.1M | $46.3M | $49.6M | $62.0M | $78.8M |
| Stockholders' equity | $181.1M | $203.1M | $241.5M | $93.1M | $42.8M | $54.1M | $67.5M | $83.2M |
| Total current assets | $182.1M | $204.9M | $247.5M | $109.8M | $59.3M | $75.8M | $100.7M | $151.1M |
| Total current liabilities | $31.0M | $31.7M | $34.2M | $44.5M | $44.5M | $49.6M | $62.0M | $78.5M |
| Cash & equivalents | $160.1M | $184.2M | $226.7M | $85.0M | $34.9M | $48.1M | $69.3M | $106.9M |
| Accounts receivable | $11.2M | $11.6M | $13.9M | $9.9M | $8.7M | $8.6M | $10.9M | $8.2M |
| Inventory | — | — | — | $25.4M | $25.4M | $25.4M | $25.9M | $27.1M |
| Other current assets | — | — | — | — | $2.4M | — | $3.7M | — |
| Property, plant & equipment | $2.2M | $1.7M | $1.4M | $1.3M | $1.4M | $1.5M | $1.5M | $1.6M |
| Other non-current assets | $1.2M | $1.2M | $110.0K | $6.0K | $15.0K | $24.0K | $34.0K | $7.5M |
| Accounts payable | $9.5M | $2.0M | $13.7M | $18.1M | $18.1M | $8.7M | $10.4M | $17.7M |
| Accrued liabilities | $19.9M | $28.0M | $19.1M | $25.3M | $25.3M | $39.9M | $50.2M | $59.4M |
| Other current liabilities | $71.0K | $56.0K | $52.0K | $32.0K | $26.0K | $34.0K | $27.0K | $20.0K |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $0 |
| Common stock & paid-in capital | $29.0K | $28.0K | $28.0K | $22.0K | $12.0K | $12.0K | $12.0K | $12.0K |
| Retained earnings | -$1.04B | -$995.9M | -$954.5M | -$943.4M | -$932.9M | -$918.3M | -$902.0M | -$883.6M |
| Accumulated other comprehensive income (loss) | -$35.0K | -$37.0K | -$41.0K | -$41.0K | -$39.0K | -$13.0K | -$5.0K | -$18.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.0M | -$41.7M | -$15.5M | -$8.2M | -$13.3M | -$21.1M | -$37.6M | -$41.1M |
| Investing cash flow | -$510.0K | -$726.0K | $0 | $0 | -$11.0K | -$144.0K | $5.0K | -$5.0K |
| Financing cash flow | $19.4M | -$98.0K | $157.2M | $58.3M | $131.0K | $10.0K | $77.0K | $61.0K |
| Free cash flow | -$43.5M | -$42.4M | -$15.5M | -$8.2M | -$13.3M | -$21.3M | -$37.6M | -$41.1M |
| Capital expenditures | $510.0K | $726.0K | $0 | $0 | $11.0K | $144.0K | -$5.0K | $5.0K |
| Share-based compensation | $2.9M | $2.7M | $2.6M | $3.1M | $3.2M | $2.8M | $3.1M | $2.9M |
| Change in accounts receivable | -$476.0K | -$2.2M | $4.1M | $1.4M | $254.0K | -$2.3M | $2.8M | $5.3M |
| Change in inventory | -$61.0K | -$47.0K | $352.0K | -$50.0K | $13.0K | $58.0K | $1.5M | $20.8M |
| Change in accounts payable | $7.3M | -$11.6M | -$4.2M | -$218.0K | $9.3M | -$1.6M | -$7.3M | $10.3M |
| Purchases of investments | — | — | — | — | — | — | $0 | $0 |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | — | — |
| Operating income | -$55.6M | -$176.9M | -$212.8M | -$248.0M | -$226.9M |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M |
| EPS (diluted) | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
| EPS (basic) | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
| Operating margin | -$104 | -$697 | — | — | — |
| Net margin | -$98 | -$669 | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 |
|---|---|---|---|---|---|
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | — |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | — |
| Stockholders' equity | $241.5M | $67.5M | $177.5M | $356.0M | — |
| Total current assets | $247.5M | $100.7M | $224.9M | $376.9M | — |
| Total current liabilities | $34.2M | $62.0M | $50.3M | $25.0M | — |
| Cash & equivalents | $226.7M | $69.3M | $200.6M | $92.1M | — |
| Accounts receivable | $13.9M | $10.9M | $0 | — | — |
| Inventory | — | $25.9M | $0 | — | — |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $1.4M | $1.5M | $1.9M | $2.3M | — |
| Other non-current assets | $110.0K | $34.0K | $175.0K | $191.0K | — |
| Accounts payable | $13.7M | $10.4M | $8.0M | $1.5M | — |
| Accrued liabilities | $19.1M | $50.2M | $40.9M | $21.9M | — |
| Other current liabilities | $52.0K | $27.0K | $35.0K | $44.0K | — |
| Other non-current liabilities | — | $0 | $700.0K | $0 | $0 |
| Common stock & paid-in capital | $28.0K | $12.0K | $11.0K | $11.0K | — |
| Retained earnings | -$954.5M | -$902.0M | -$732.1M | -$533.4M | — |
| Accumulated other comprehensive income (loss) | -$41.0K | -$5.0K | -$13.0K | -$272.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$58.1M | -$170.5M | -$173.2M | -$220.0M | -$184.7M |
| Investing cash flow | -$155.0K | -$140.0K | $280.7M | -$230.7M | -$50.7M |
| Financing cash flow | $215.6M | $39.3M | $1.0M | $506.0K | $662.7M |
| Free cash flow | -$58.3M | -$170.6M | -$173.8M | -$221.7M | -$184.8M |
| Capital expenditures | $155.0K | $140.0K | $615.0K | $1.7M | $84.0K |
| Share-based compensation | $11.6M | $19.8M | $18.7M | $21.6M | $17.8M |
| Change in accounts receivable | $3.3M | $10.9M | $0 | — | — |
| Change in inventory | $373.0K | $24.9M | $0 | — | — |
| Change in accounts payable | $3.2M | $2.4M | $6.5M | -$4.3M | -$2.4M |
| Purchases of investments | — | $0 | $91.2M | $298.0M | $188.6M |
| Share repurchases | — | $0 | $1.0K | $4.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IVVD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-19 to 2026-08-18
Recent transactions
- Insiders have net sold 228,024 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: Lee Timothy Edward (Chief Commercial Officer) — Open market sale of 18,425 shares on 2026-08-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)228,024 sh(10 txns)
Net Shares-228,024
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer | Open market sale | 2026-08-18 | 18,425 |
| Green Julie | Chief Human Resources Officer | Open market sale | 2026-08-18 | 18,425 |
| Duke William E. | Chief Financial Officer | Open market sale | 2026-08-18 | 18,425 |
| Andersen Jill | Chief Legal Officer, Secretary | Open market sale | 2026-08-18 | 30,706 |
| Allen Robert D. III | Chief Scientific Officer | Open market sale | 2026-08-18 | 17,043 |
| MCLAUGHLIN KEVIN F | Reporting person | Open market purchase | 2025-11-19 | 50,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Lee Timothy Edward | Chief Commercial Officer | Open market sale | 18,425 | $0.84 |
| 2026-08-18 | Green Julie | Chief Human Resources Officer | Open market sale | 18,425 | $0.84 |
| 2026-08-18 | Duke William E. | Chief Financial Officer | Open market sale | 18,425 | $0.84 |
| 2026-08-18 | Andersen Jill | Chief Legal Officer, Secretary | Open market sale | 30,706 | $0.84 |
| 2026-08-18 | Allen Robert D. III | Chief Scientific Officer | Open market sale | 17,043 | $0.84 |
| 2026-08-17 | Lee Timothy Edward | Chief Commercial Officer | Open market sale | 22,355 | $0.72 |
| 2026-08-17 | Green Julie | Chief Human Resources Officer | Open market sale | 22,355 | $0.72 |
| 2026-08-17 | Duke William E. | Chief Financial Officer | Open market sale | 22,355 | $0.72 |
| 2026-08-17 | Andersen Jill | Chief Legal Officer, Secretary | Open market sale | 37,256 | $0.72 |
| 2026-08-17 | Allen Robert D. III | Chief Scientific Officer | Open market sale | 20,679 | $0.72 |
| 2026-08-15 | Lee Timothy Edward | Chief Commercial Officer | Option exercise | 102,000 | — |
| 2026-08-15 | Green Julie | Chief Human Resources Officer | Option exercise | 102,000 | — |
| 2026-08-15 | Duke William E. | Chief Financial Officer | Option exercise | 102,000 | — |
| 2026-08-15 | Andersen Jill | Chief Legal Officer, Secretary | Option exercise | 170,000 | — |
| 2026-08-15 | Allen Robert D. III | Chief Scientific Officer | Option exercise | 102,000 | — |
| 2026-02-18 | Allen Robert D. III | Chief Scientific Officer | Open market sale | 19,392 | $1.58 |
| 2026-02-18 | Green Julie | Chief Human Resources Officer | Open market sale | 20,964 | $1.58 |
| 2026-02-18 | Duke William E. | Chief Financial Officer | Open market sale | 20,964 | $1.58 |
| 2026-02-18 | Lee Timothy Edward | Chief Commercial Officer | Open market sale | 20,964 | $1.58 |
| 2026-02-18 | Andersen Jill | Chief Legal Officer, Secretary | Open market sale | 34,939 | $1.58 |
| 2026-02-17 | Allen Robert D. III | Chief Scientific Officer | Open market sale | 18,189 | $1.54 |
| 2026-02-17 | Green Julie | Chief Human Resources Officer | Open market sale | 19,663 | $1.54 |
| 2026-02-17 | Duke William E. | Chief Financial Officer | Open market sale | 19,663 | $1.54 |
| 2026-02-17 | Lee Timothy Edward | Chief Commercial Officer | Open market sale | 19,663 | $1.54 |
| 2026-02-17 | Andersen Jill | Chief Legal Officer, Secretary | Open market sale | 32,771 | $1.54 |
| 2026-02-15 | Allen Robert D. III | Chief Scientific Officer | Option exercise | 99,000 | — |
| 2026-02-15 | Green Julie | Chief Human Resources Officer | Option exercise | 99,000 | — |
| 2026-02-15 | Duke William E. | Chief Financial Officer | Option exercise | 99,000 | — |
| 2026-02-15 | Lee Timothy Edward | Chief Commercial Officer | Option exercise | 99,000 | — |
| 2026-02-15 | Andersen Jill | Chief Legal Officer, Secretary | Option exercise | 165,000 | — |
| 2025-11-19 | MCLAUGHLIN KEVIN F | Reporting person | Open market purchase | 50,000 | $2.50 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-30 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-08-30 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
Recent news
Headlines about IVVD (Invivyd, Inc.). Links open the publisher — we don’t host full articles.
-
Invivyd presents preclinical data on measles antibody candidate By Investing.com
Investing.com Australia · 2026-10-21 -
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Yahoo · 2026-10-21 -
Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants
Benzinga · 2026-10-21 -
COVID-19 drugmaker Invivyd expands in New Haven as new CEO pursues broader drug market
Hartford Business Journal · 2026-10-20 -
Invivyd (IVVD) Stock Today: Drops -7.51%, Key Support at $0.59 2026-10-17 - Spring Pattern
https://www.siam.in/ · 2026-10-17 -
IVVD Nov 2026 1.000 put (IVVD261120P00001000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-17 -
IVVD Nov 2026 1.000 put (IVVD261120P00001000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
IVVD Nov 2026 1.000 call (IVVD261120C00001000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-17
No headlines in this category right now — try “All”.